Form 4: Apellis Pharmaceuticals Executive Granted Future Restricted Stock Units

Apellis Pharmaceuticals, Inc. announced that its VP/Chief Accounting Officer, James George Chopas, was granted 6,250 restricted stock units with a future grant date of June 18, 2025.

Summary

• James George Chopas, the VP/Chief Accounting Officer of Apellis Pharmaceuticals, Inc. (APLS), was granted 6,250 shares of common stock in the form of restricted stock units (RSUs).
• The grant date for these restricted stock units is specified as June 18, 2025.
• The RSUs were acquired at a price of $0, which is typical for equity compensation grants.
• Following this transaction, Mr. Chopas's beneficial ownership of common stock totals 54,205 shares.
• The granted restricted stock units are scheduled to vest over a two-year period, with 50% vesting on the one-year anniversary and the remaining 50% on the two-year anniversary of the June 18, 2025 grant date, contingent upon his continued service to the company.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is a positive for executive retention and aligns their interests with long-term shareholder value, reflecting standard corporate governance practices. It is a routine compensation event and not indicative of significant positive or negative operational performance.

Positives

• The grant of restricted stock units aligns the executive's financial interests with those of shareholders, encouraging long-term value creation.
• The two-year vesting schedule promotes executive retention by incentivizing continued service from a key officer (VP/Chief Accounting Officer).

Negatives

• The grant does not provide immediate cash liquidity to the executive, as it is in the form of restricted stock units that vest over time.
• There is potential for minor future dilution of existing shareholders upon the vesting and conversion of these restricted stock units into common stock.

Risks

• The vesting of the restricted stock units is contingent upon the executive's continued employment, meaning the shares will be forfeited if service is terminated before vesting dates.

Future Outlook

The vesting schedule for the restricted stock units indicates future share issuance on the one-year and two-year anniversaries of the June 18, 2025 grant date, contingent upon the executive's continued service.

Industry Context

This Form 4 filing details a routine executive compensation event. The grant of restricted stock units is a common practice in the pharmaceutical and biotechnology industries, as well as across publicly traded companies, to incentivize and retain key management personnel by aligning their long-term interests with shareholder value.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to key executives, such as the VP/Chief Accounting Officer, is a standard and widely adopted practice across the pharmaceutical sector and broader public company landscape, comparable to compensation structures at companies like Regeneron Pharmaceuticals, Inc. or Gilead Sciences, Inc.
• The two-year vesting period, with 50% vesting annually, is a typical RSU vesting schedule designed to promote executive retention and long-term commitment, consistent with industry benchmarks.
• The acquisition price of $0 for RSUs is standard, as these grants represent a right to receive shares upon the fulfillment of vesting conditions, rather than a direct purchase.

Related Party Transactions

• Grant of 6,250 restricted stock units to James George Chopas, VP/Chief Accounting Officer, as part of his executive compensation package.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of RSUs; improved alignment of executive interests with long-term shareholder value.
• Employees: Signals standard and competitive executive compensation practices within the company.
• Management: Increases the equity stake and long-term incentive for the VP/Chief Accounting Officer.

Next Steps

• Vesting of 50% of the restricted stock units on June 18, 2026 (one-year anniversary of the grant date), contingent on continued service.
• Vesting of the remaining 50% of the restricted stock units on June 18, 2027 (two-year anniversary of the grant date), contingent on continued service.

Key Dates

Recommendation

Keywords

Apellis Pharmaceuticals, APLS, SEC Form 4, restricted stock units, RSU grant, executive compensation, insider transaction, James Chopas, equity compensation